Brief: Scynexis Entered Into License Agreement With GSK
30/03/2023 12:29
March 30 (Reuters) - GSK plc GSK.L :
* SCYNEXIS INC - ENTERED INTO LICENSE AGREEMENT WITH
GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED
Source text for Eikon: ID:
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Scynexis
See all newsBrief: Scynexis Announces Phase 1 Study Results For Scy-770, A Novel, Highly Selective, Oral Direct Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview